Les inhibiteurs des SGLT-2 dans la prise en charge du diabète de type 2

Buysschaert, Martin;Preumont, Vanessa
(2018) Louvain médical — Vol. 137, n° 9, p. 506-509 (2018)

Files

2018_Buysschaert_LM_137_506-509.pdf
  • Restricted Access
  • Adobe PDF
  • 74.91 KB
Request a copy

Details

Authors
Abstract
(en) [SGLT-2 inhibitors in type 2 diabetes care] SGLT-2 inhibitors (gliflozins) are a new therapeutic class for managing Type 2 diabetes, acting by their glucoretic effect. Along with their glycemic action, these agents likewise exhibit cardiovascular and renal benefits.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Buysschaert, M., & Preumont, V. (2018). Les inhibiteurs des SGLT-2 dans la prise en charge du diabète de type 2. Louvain médical, 137(9), 506-509. https://hdl.handle.net/2078.5/58838 (Original work published 2018)